At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Patrick Schöffski, MD, of University Hospitals Leuven, Leuven, Belgium, discusses the results of a randomised, open-label, multicentre, phase 3 trial of the microtubule dynamics inhibitor, eribulin, versus dacarbazine for the treatment of patients with advanced liposarcoma or leiomyosarcoma.
